Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

312
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
312
Clinically Relevant Drug Product Specifications: Methods of Establishment01:29

Clinically Relevant Drug Product Specifications: Methods of Establishment

279
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
279
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

336
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
336
Drug Product Performance: In Vitro–In Vivo Correlation01:20

Drug Product Performance: In Vitro–In Vivo Correlation

344
In pharmaceutical development, it's crucial to establish a predictive in vitro–in vivo correlation (IVIVC) for two or more formulations to gain a comprehensive understanding of release properties. IVIVC reduces the need for costly in vivo studies and facilitates the establishment of meaningful dissolution specifications with significant cost savings and decreased regulatory burden. Furthermore, a meaningful IVIVC should predict Cmax and AUC within 20%, aligning with FDA guidance while...
344
Biopharmaceutical Factors Influencing Drug Product Design: Overview01:22

Biopharmaceutical Factors Influencing Drug Product Design: Overview

402
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
402
Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules01:18

Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules

396
Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
396

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Turning Employees into Compliance Assets: Managing and Preventing Claims Based on Failed OBRA '90 and USP <800> Compliance.

International journal of pharmaceutical compounding·2026
Same author

Legal Challenges to Compounding Drugs for Weight Loss.

International journal of pharmaceutical compounding·2025
Same author

One Decade In and Counting: How 503B Outsourcing Facilities Are Finding Their Place in the Industry.

International journal of pharmaceutical compounding·2025
Same author

Advertising and Marketing for Compounding Pharmacies: Many Shades of Grey.

International journal of pharmaceutical compounding·2025
Same author

Navigating the Direct Importation of Active Pharmaceutical Ingredients: Compliance Considerations for Compounding Pharmacies.

International journal of pharmaceutical compounding·2025
Same author

A Collision Avoidance Algorithm for Human Motion Prediction Based on Perceived Risk of Collision: Part 2-Application.

IISE transactions on occupational ergonomics and human factors·2021

Related Experiment Video

Updated: Mar 14, 2026

An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use
10:33

An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use

Published on: May 24, 2024

1.7K

Between Necessity and Compliance: Understanding FDA's GFI #256 for Animal Drug Compounding.

Jordan T Vogel1, Brad Howard2

  • 1Brown & Fortunato, P.C., Amarillo and Dallas, Texas.

International Journal of Pharmaceutical Compounding
|March 12, 2026
PubMed
Summary

The FDA

Area of Science:

  • Veterinary Pharmacy
  • Regulatory Affairs
  • Animal Drug Compounding

Background:

  • Compounding animal drugs from bulk substances historically operated in a regulatory gray zone.
  • The Federal Food, Drug, and Cosmetic Act (FDCA) governs this practice.
  • The Food and Drug Administration (FDA) traditionally exercised enforcement discretion.

Purpose of the Study:

  • To explore the practical implications of FDA's Guidance for Industry #256 (GFI #256).
  • To clarify regulatory requirements for compounding animal drugs using bulk substances.
  • To assist veterinarians and compounders in meeting FDA expectations.

Main Methods:

  • Analysis of FDA's Guidance for Industry #256.
  • Focus on three critical requirements for compounding bulk drug substances.

More Related Videos

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
09:30

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Published on: March 17, 2023

4.6K
Wet-spinning-based Molding Process of Gelatin for Tissue Regeneration
06:56

Wet-spinning-based Molding Process of Gelatin for Tissue Regeneration

Published on: March 7, 2019

9.4K

Related Experiment Videos

Last Updated: Mar 14, 2026

An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use
10:33

An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use

Published on: May 24, 2024

1.7K
Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
09:30

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Published on: March 17, 2023

4.6K
Wet-spinning-based Molding Process of Gelatin for Tissue Regeneration
06:56

Wet-spinning-based Molding Process of Gelatin for Tissue Regeneration

Published on: March 7, 2019

9.4K
  • Examination of regulations for non-food-producing animals under patient-specific prescriptions.

    • Main Results:

    • GFI #256 outlines specific conditions for FDA enforcement discretion.
    • Identifies key compliance requirements for veterinary drug compounding.
    • Provides a framework for legal and compliant compounding practices.

    Conclusions:

    • Adherence to GFI #256 is crucial for veterinarians and compounders.
    • Understanding and implementing the guidance ensures regulatory compliance.
    • Facilitates safe and effective compounded animal drug preparations.